Loading…
Cybin D/B/A Helus Pharma is projected to rise to $5.68 by 2027, a +28% move from its current price of $4.43. HELP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.26 | $4.43 | $4.61 | +0.07% |
| May 30 | $4.20 | $4.44 | $4.69 | +0.14% |
| May 31 | $4.15 | $4.44 | $4.75 | +0.22% |
| Jun 1 | $4.11 | $4.44 | $4.80 | +0.29% |
| Jun 2 | $4.08 | $4.45 | $4.85 | +0.36% |
| Jun 3 | $4.05 | $4.45 | $4.89 | +0.43% |
| Jun 4 | $4.02 | $4.45 | $4.93 | +0.51% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.02 | $4.45 | $4.93 | +0.51% |
| Week 2 | $3.87 | $4.48 | $5.18 | +1.02% |
| Week 3 | $3.76 | $4.50 | $5.37 | +1.53% |
| Week 4 | $3.68 | $4.52 | $5.55 | +2.04% |
| Week 5 | $3.61 | $4.54 | $5.72 | +2.56% |
| Week 6 | $3.55 | $4.57 | $5.87 | +3.08% |
| Week 7 | $3.50 | $4.59 | $6.02 | +3.61% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cybin D/B/A Helus Pharma is a clinical-stage neuropsychiatry company focused on developing psychedelic-based therapeutics for mental health conditions. It advances CYB003, a deuterated psilocybin analog, in phase 3 clinical trials to treat major depressive disorder, and CYB004, a deuterated N, N-dimethyltryptamine (DMT), in phase 2 trials for generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT (completed phase 1), SPL026 for MDD, and CYB005, a phenethylamine derivative in preclinical stages, along with a research pipeline of investigational psychedelic-based compounds.
Hedged by a strategic partnership with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for adjunctive treatment of MDD. The organization is headquartered in Toronto, Canada.
HELP is Cybin D/B/A Helus Pharma, operating in the Healthcare sector as a clinical-stage neuropsychiatry company. The current price is $4.68 and the market cap stands at $233.5M with a rank of 3732. These figures place the asset among mid-cap healthcare names with ongoing psychedelic-based therapeutics development.
A major floor 27.7% below — a decisive break under it would weaken the trend.
The nearest floor, 5.6% below — buyers have tended to step in here.
The nearest ceiling, 30.2% above — a clean break opens room to run.
A major ceiling 92.6% above — clearing it would confirm fresh momentum.
Key HELP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HELP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.50 | Sell | $4.50 | Sell |
| MA 10 | $4.60 | Sell | $4.62 | Sell |
| MA 20 | $4.91 | Sell | $4.82 | Sell |
| MA 50 | $5.03 | Sell | $5.19 | Sell |
| MA 100 | $5.95 | Sell | $5.64 | Sell |
| MA 200 | $6.22 | Sell | $6.26 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 39.80 | Neutral |
| Stoch RSI (14) | 42.55 | Neutral |
| CCI (20) | -91.08 | Neutral |
| Williams %R (14) | -78.45 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -16.57 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 21.55 | Neutral |
| TRIX (15) | -0.48 | Sell |
| Awesome (5,34) | -0.63 | Sell |
| Ultimate (7,14,28) | 36.43 | Neutral |
| Momentum (10) | -0.63 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 4.52 | Sell |
| ADX (14) | 14.62 | Neutral |
| ATR (14) | 0.18 | Info |
The near-term picture is Bearish in sentiment. The RSI(14) is 40, and the stock is trading below key moving averages, with the SMA50 at $5.04 and the SMA200 at $6.25. Support is noted at $4.18 and resistance at $5.77, framing a cautious price topology.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.18 | $4.43 | $6.37 | 0% | Neutral | |
| $4.32 | $5.68 | $8.02 | +28% | Bullish | |
| $4.49 | $6.14 | $9.09 | +39% | Bullish | |
| $3.94 | $5.59 | $8.58 | +26% | Bullish | |
| $3.80 | $5.55 | $8.79 | +25% | Bullish | |
| $3.97 | $5.97 | $9.72 | +35% | Bullish | |
| $4.87 | $7.53 | $12.56 | +70% | Bullish | |
| $5.39 | $8.53 | $14.56 | +93% | Bullish | |
| $5.00 | $8.12 | $14.14 | +83% | Bullish | |
| $4.89 | $8.13 | $14.41 | +83% | Bullish | |
| $6.59 | $12.22 | $23.41 | +176% | Bullish | |
| $9.56 | $21.24 | $45.50 | +379% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $4.18 | $4.43 | $5.21 | +0.00% |
| June 2026 | $3.75 | $4.44 | $5.42 | +0.27% |
| July 2026 | $3.94 | $4.73 | $5.88 | +6.53% |
| August 2026 | $3.98 | $4.82 | $6.08 | +1.83% |
| September 2026 | $3.83 | $4.67 | $5.96 | -3.02% |
| October 2026 | $3.86 | $4.75 | $6.13 | +1.65% |
| November 2026 | $3.99 | $4.93 | $6.42 | +3.82% |
| December 2026 | $3.90 | $4.85 | $6.37 | -1.63% |
Click any year to see its month-by-month HELP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, HELP could reach as high as $6.37, with a base case around $4.43 and support toward $4.18 — roughly 0% from $4.43. Price action looks broadly range-bound.
Expect HELP to range from $4.32 to $8.02 through 2027. The $5.68 average target implies a +28% move from current prices. That is up +28% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The HELP price prediction for 2028 points to an average of $6.14 (low $4.49, high $9.09) — a potential gain of +39% on today's $4.43. Momentum favours further upside here.
In 2029, HELP is projected to trade between $3.94 and $8.58, averaging $5.59 — a potential gain of +26% from today's $4.43. That is -9% versus the projected 2028 average. Buyers look set to stay in control over this stretch.
Cybin D/B/A Helus Pharma's 2030 outlook centres on $5.55, within a $3.80 to $8.79 range. That is -1% versus the projected 2029 average. That marks a +25% change versus current levels. Momentum favours further upside here.
By 2031, HELP could reach as high as $9.72, with a base case around $5.97 and support toward $3.97 — roughly +35% from $4.43. Buyers look set to stay in control over this stretch.
Expect HELP to range from $4.87 to $12.56 through 2032. The $7.53 average target implies a +70% move from current prices. That is up +26% on the projected 2031 average. Momentum favours further upside here.
The HELP price prediction for 2033 points to an average of $8.53 (low $5.39, high $14.56) — a potential gain of +93% on today's $4.43. Buyers look set to stay in control over this stretch.
In 2034, HELP is projected to trade between $5.00 and $14.14, averaging $8.12 — a potential gain of +83% from today's $4.43. That is -5% versus the projected 2033 average. Momentum favours further upside here.
Cybin D/B/A Helus Pharma's 2035 outlook centres on $8.13, within a $4.89 to $14.41 range. That is up 0% on the projected 2034 average. That marks a +83% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, HELP could reach as high as $23.41, with a base case around $12.22 and support toward $6.59 — roughly +176% from $4.43. Momentum favours further upside here.
Expect HELP to range from $9.56 to $45.50 through 2050. The $21.24 average target implies a +379% move from current prices. That is up +74% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in HELP today (≈ 225.733634 HELP) could be worth
$4,794.5
+$3,794.5 (+379%) by 2050 · US Dollar
Based on the average projected HELP price of $21.24 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HELPwould be worth at today's price.
$1,000 invested in HELP on May 27, 2025 (≈ 119.904075 HELP) would be worth
$531.18
-$468.82 (-46.9%) today · 0.53× · US Dollar
Based on a HELP entry price of $8.34 vs. today's $4.43.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.34 | $1,020.74 | +2.1% |
| 1 month ago | $5.4 | $820.37 | -18.0% |
| 3 months ago | $7.76 | $570.88 | -42.9% |
| 6 months ago | $6.18 | $716.83 | -28.3% |
| 1 year ago | $8.34 | $531.18 | -46.9% |
| All time (5.0y) ago | $54.23 | $81.7 | -91.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HELP forecast.
Our base-case forecast reaches $8.90 around 2040.
Implied market cap at $8.90: $444.06M
The multi-year forecast shows a bullish trend across most future years, with notable upside by 2032 and beyond. For 2026 the min/avg/max are $4.18/$4.68/$6.76 with ROI 0 and Neutral sentiment; 2027 shows $4.60/$6.07/$8.60 with ROI 29.7 and Bullish sentiment; 2028 shows $4.79/$6.59/$9.80 with ROI 40.7 and Bullish sentiment. By 2030 the min/avg/max are $4.07/$5.98/$9.55 with ROI 27.9 and Bullish sentiment; 2040 shows $7.23/$13.63/$26.37 with ROI 191.2 and Bullish sentiment; 2050 shows $10.82/$24.04/$52.07 with ROI 413.6 and Bullish sentiment.
These figures depict a steady trajectory upward through mid-century, culminating in a high-end price path, while noting that these are estimates and not guarantees.
Tap a question to reveal the answer.
2030: min $4.07, avg $5.98, max $9.55; ROI 27.9; sentiment BULLISH.
The long-term forecast shows bullish sentiment in multiple years with expanding average values and positive ROI figures (e.g., 2027 ROI 29.7, 2040 ROI 191.2, 2050 ROI 413.6). These are estimates and not guarantees.
According to the forecast, the max by 2050 is $52.07, suggesting a path that could reach around that level under the modeled scenario.
Current price: $4.68. Market cap: $233.5M.
RSI(14) is 40; SMA50 is $5.04 and SMA200 is $6.25. Support is $4.18 and resistance is $5.77. The 30-day range is $3.60 to $6.08.
Cybin D/B/A Helus Pharma Community Discussion
0Share your Cybin D/B/A Helus Pharma price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.